{"id":4146,"date":"2025-03-31T18:11:59","date_gmt":"2025-03-31T18:11:59","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/linezolid-txt\/"},"modified":"2025-03-31T18:11:59","modified_gmt":"2025-03-31T18:11:59","slug":"linezolid-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/linezolid-txt\/","title":{"rendered":"Linezolid.txt"},"content":{"rendered":"

Linezolid <\/h1>\n

CLINICAL USE <\/H3>
\nAntibacterial agent

DOSE IN NORMAL RENAL FUNCTION <\/H3>600 mg twice daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :337.3<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :31<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 30<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.6<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :5\u20137\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function, but monitor closely.

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Likely to be dialysed. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • HDF\/high flux &nbsp :Dialysed. Dose as in GFR
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in normal renal functionCVVhdFDialysed. Dose as in normal renal function1

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Antidepressants: increased risk of serotonergic syndrome with SSRIs and tricyclics; avoid concomitant use with MAOIs, moclobemideSelegiline: avoid concomitant use\n
  • Sympathomimetics: enhanced hypertensive effect with adrenaline, noradrenaline, dopamine, dobutamine, phenylpropanolamine and pseudoephedrine \u2013 use with caution

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral, IV

    Rate of Administration <\/H4>Over 30\u2013120 minutes

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>30% of dose is removed by a 3 hour haemodialysis sessionIn patients with GFR <10 mL\/min, if platelet count drops on a dose of 600 mg twice daily, consider reducing dose to 600 mg once dailyTwo metabolites accumulate in renal failure which have MAOI activity but no antibacterial activity \u2013 monitor patients closelyThere is 5 mmol sodium per 300 mL infusionLinezolid is a weak, reversible non- selective inhibitor of MAO therefore can be used with drugs not normally given with MAOIs (e.g. SSRIs) but monitor closelyIn patients who have been on linezolid for longer than 28 days, there have been reports of peripheral neuropathy and\/or optic neuropathy occasionally leading to loss of vision, anaemia requiring transfusions, and lactic acidosis \u2013 visual function should be monitored in these patientsAfter oral or IV administration, adequate drug concentrations can be found in PF fluid to treat VRE peritonitis. (Salzer W. Antimicrobial-resistant gram-positive bacteria in PD peritonitis.
    \n","protected":false},"excerpt":{"rendered":"

    Linezolid CLINICAL USE Antibacterial agent DOSE IN NORMAL RENAL FUNCTION<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4146","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4146"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4146\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}